Kidney stone laboratory findings

Jump to navigation Jump to search

Kidney stone Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kidney stone from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Ultrasonography

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kidney stone laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kidney stone laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Kidney stone laboratory findings

CDC on Kidney stone laboratory findings

Kidney stone laboratory findings in the news

Blogs onKidney stone laboratory findings

Directions to Hospitals Treating Kidney stone

Risk calculators and risk factors for Kidney stone laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

Laboratory findings consistent with the diagnosis of nephrolithiasis include hypercalcemia, hypercalciuria, hyperoxaluria, hypocitraturia, hyperuricemia and hyperuricosuria

Laboratory Findings

The urine calcium/creatinine ratio should be less than 0.14[1]. Higher values suggest hypercalcuria.

The urine calcium to urinary citrate ratio (UCa/Ucit) is not well studied, but should maybe be < 0.7[2] Higher values may suggest hyperparathyroidism.

References

  1. Foley, Kevin F.; Boccuzzi, Lorenzo (2010). "Urine Calcium: Laboratory Measurement and Clinical Utility". Laboratory Medicine. 41 (11): 683–686. doi:10.1309/LM9SO94ZNBHEDNTM. ISSN 0007-5027.
  2. Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA; et al. (2018). "Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity". J Bone Miner Res. 33 (10): 1741–1747. doi:10.1002/jbmr.3480. PMID 29878514.

Template:WH Template:WS